{
"id":"mk19_b_en_q045",
"number":45,
"bookId":"en",
"correctAnswer":"A",
"title":"Question 45",
"stimulus":[
{
"type":"p",
"hlId":"33053a",
"children":[
"A 28-year-old woman is evaluated for a 2-month history of sleeplessness. She has had panhypopituitarism since surgery for a craniopharyngioma at age 15 years. Medical history includes hypoadrenalism, hypogonadism, and hypothyroidism. She is taking estrogen, progesterone, hydrocortisone, and levothyroxine."
]
},
{
"type":"p",
"hlId":"44832f",
"children":[
"On physical examination, vital signs are normal. A small atrophic thyroid is noted; her hands are warm and dry, and no lower extremity edema or tremor is evident."
]
},
{
"type":"p",
"hlId":"94f509",
"children":[
"A ",
{
"type":"reference-range-link",
"referenceRange":"Thyroid-stimulating hormone (TSH)",
"children":[
"thyroid-stimulating hormone"
]
},
" level mistakenly obtained at her last office appointment was less than 0.01 Î¼U/mL (0.01 mU/L)."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Free thyroxine measurement"
}
},
{
"letter":"B",
"text":{
"__html":"Levothyroxine discontinuation"
}
},
{
"letter":"C",
"text":{
"__html":"Thyroid scintigraphy with radioactive iodine uptake"
}
},
{
"letter":"D",
"text":{
"__html":"Thyroid-stimulating immunoglobulin measurement"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"0326ee",
"children":[
"Measuring serum thyroid-stimulating hormone alone is sufficient to monitor thyroid replacement therapy except in central hypothyroidism, for which free thyroxine measurement is the laboratory test of choice."
]
},
{
"type":"keypoint",
"hlId":"f6b127",
"children":[
"In patients with central hypothyroidism, free thyroxine levels can be checked 2 to 3 weeks after a dose change to assess for adequacy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"87dca1",
"children":[
"The most appropriate management is free thyroxine (T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
") measurement (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Measuring serum thyroid-stimulating hormone (TSH) alone is sufficient to monitor thyroid replacement therapy in most patients, but not in patients with central hypothyroidism, for whom free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" measurement is the laboratory test of choice. In patients with panhypopituitarism, deficiency of TSH results in the inability of the thyroid gland to produce T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
". The result is insufficient T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" production with low or inappropriately normal TSH. Because TSH cannot be used to monitor therapy, it should not be measured. In patients with central hypothyroidism, dosing based on TSH level can lead to underdosing. Free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" should be used to monitor dose adequacy and should be maintained in the mid to upper half of the normal range. In primary hypothyroidism, the time range is 6 to 8 weeks for TSH to accurately reflect thyroid hormone status, whereas in secondary hypothyroidism, free T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" levels can be checked 2 to 3 weeks after a dose change to assess for adequacy."
]
},
{
"type":"p",
"hlId":"6d92d2",
"children":[
"In patients with normal pituitary function, an undetectable TSH in a patient taking levothyroxine suggests overtreatment and the need for levothyroxine discontinuation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). However, this patient has panhypopituitarism with central hypothyroidism, and thus TSH is an unreliable measure of thyroid function. T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" measurement should guide levothyroxine replacement in patients with central hypothyroidism."
]
},
{
"type":"p",
"hlId":"9018ee",
"children":[
"Thyroid scintigraphy with radioactive iodine uptake (RAIU) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") would be helpful to assess thyrotoxicosis unless contraindicated, such as during pregnancy or lactation. Although this patient has no apparent contraindication to thyroid scintigraphy, she is taking levothyroxine, which decreases RAIU uptake; therefore, scintigraphy with RAIU will have limited usefulness in the event that thyrotoxicosis is diagnosed in this patient."
]
},
{
"type":"p",
"hlId":"0c0a49",
"children":[
"Thyroid-stimulating immunoglobulin (TSI) measurement (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is useful to assess thyrotoxicosis when RAIU is unavailable or unreliable or when thyroid scintigraphy is contraindicated. However, because thyrotoxicosis has not been established in this patient, there is no indication for TSI measurement."
]
}
],
"relatedSection":"mk19_b_en_s4_4",
"objective":{
"__html":"Monitor thyroid function in a patient with pituitary disease."
},
"references":[
[
"Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24:1670-751. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25266247",
"target":"_blank"
},
"children":[
"PMID: 25266247"
]
},
" doi:10.1089/thy.2014.0028"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":86,
"B":8,
"C":3,
"D":3,
"E":0
},
"hlIds":[
"33053a",
"44832f",
"94f509",
"cb2b54",
"0326ee",
"f6b127",
"87dca1",
"6d92d2",
"9018ee",
"0c0a49"
]
}